Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.

Objective: Our objective is to examine how selenium (Se) supplementation influences oxidative stress (malondialdehyde) and the glutathione peroxidase system in patients with ovarian cancer undergoing chemotherapy.

Material: The study group included 31 patients with ovarian cancer undergoing chemotherapy receiving the drug Protecton Zellactiv (Smith Kline Beecham, Fink Naturarznei GmbH, Germany), two capsules, four times daily (200 microg).

Results: Following the Se supplementation in a daily dose of 200 microg, the concentration of this microelement in serum (P < 0.